Dalbavancin (Xydalba®)

Assessment Status Rapid review complete
Drug Dalbavancin
Brand Xydalba®
Indication Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Assessment Process
Rapid review commissioned 07/03/2017
Rapid review completed 28/04/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations November 2017.